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Abstract
Marfan syndrome (MFS) is an autosomal dominant genetic disorder caused by
mutations in the FBN1 gene. Although many peripheral tissues are affected, aortic
complications, such as dilation, dissection and rupture, are the leading causes of MFS‐
related mortality. Aberrant TGF‐beta signalling plays a major role in the pathophysiol-
ogy of MFS. However, the contributing mechanisms are still poorly understood. Here,
we aimed at identifying novel aorta‐specific pathways involved in the pathophysiology
of MFS. For this purpose, we employed the Fbn1 under‐expressing mgR/mgR mouse
model of MFS. We performed RNA‐sequencing of aortic tissues of 9‐week‐old mgR/
mgR mice compared with wild‐type (WT) mice. With a false discovery rate <5%, our
analysis revealed 248 genes to be differentially regulated including 20 genes previ-
ously unrelated with MFS‐related pathology. Among these, we identified Igfbp2, Ccl8,
Spp1,Mylk2,Mfap4, Dsp and H19. We confirmed the expression of regulated genes by
quantitative real‐time PCR. Pathway classification revealed transcript signatures
involved in chemokine signalling, cardiac muscle contraction, dilated and hypertrophic
cardiomyopathy. Furthermore, our immunoblot analysis of aortic tissues revealed
altered regulation of pSmad2 signalling, Perk1/2, Igfbp2, Mfap4, Ccl8 and Mylk2
protein levels in mgR/mgR vs WT mice. Together, our integrative systems approach
identified several novel factors associated with MFS‐aortic‐specific pathophysiology
that might offer potential novel therapeutic targets for MFS.
K E YWORD S
Chemokine signalling, Igfbp2 signalling, Marfan syndrome, Mfap4, mgR/mgR, RNA-sequencing,
Spp1, TGF-beta signalling, Transcriptomics
1 | INTRODUCTION
Marfan syndrome (MFS) is an inherited autosomal connective tissue
disorder caused by mutations in an extracellular matrix protein, fib-
rillin‐1 (FBN1), with manifestations in the cardiovascular system, eye,
skeleton, lung, skin and dura.1 The major complication is aortic dis-
section, which generally occurs in the presence of aortic root dilata-
tion. In MFS, the extracellular matrix undergoes remodelling with
increase in aortic stiffness and progressive weakening of the aortic
wall leading to aortic dissection.
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Extensive research has been conducted using mouse models with
mutant fibrillin‐1 (Fbn1) that develop MFS‐like aortopathy despite
normal aortic elastogenesis.2–4 Two mice models, Fbn1C1039G/+ and
mgR/mgR with different degrees of MFS pathologies, have fre-
quently been used in MFS studies.3–6 In the Fbn1C1039G/+ model, it
has been observed that 90% of animals develop the variable severe
phenotype and ~5% of animals die by 8 months of age as a result of
aortic aneurysms.5 On contrary, the mgR/mgR (hypomorphic) model
produces ~20% normal fibrillin1 that develops a severe form of MFS
with an earlier onset and an average survival of 2.5 months.2,7
Previous research has suggested that the pathophysiology of MFS
can be explained by ongoing abnormalities in TGF‐beta signalling that
lead to progressive destabilization of the aortic wall and it has been
suggested that fibrillin‐1 interacts with latent TGF‐beta binding pro-
teins (LTBPs) to restrict TGF‐beta activation.8,9 Hence, the deficiency
of fibrillin‐1 in MFS promotes the release and activation of TGF‐beta.
Several studies have shown that there is an increased abundance of
TGF‐beta in MFS.8,10 In addition, non‐canonical TGF‐beta signalling
pathway (extracellular signal‐regulated kinase [ERK] 1 and 2) has also
been shown to promote aortic aneurysms in Marfan mice.11 TGF‐beta
neutralizing antibodies (1D11) and Losartan (an angiotensin II type 1
receptor [AT1] antagonist) have been shown to decrease TGF‐beta
signalling in Marfan mouse models. Furthermore, aortic extracts con-
taining elastin/fibrillin fragments with GxxPG motifs significantly
increased macrophage chemotaxis.12,13 Subsequent treatment of Mar-
fan mice with a neutralizing antibody (BA4 ‐ anti‐elastin, monoclonal
antibody) decreased macrophage chemotaxis, inflammation and
degeneration of the vessel architecture.12
Overall, in the last decade, the leading hypothesis has been that
TGF‐beta induction is a major driver of Marfan disease progression.
This assumption was recently challenged by selectively deleting the
TGF‐type‐II receptor in MFS mice (Fbn1C1039G/+) suggesting that
increased TGF‐beta in MFS may not be the sole cause of MFS aor-
topathy.14 Consequently, these results suggest that there may be
previously unrecognized mechanisms, by which MFS disease pro-
gression is regulated and potential etiologies of MFS need further
examination.
With an aim to gain insight into the molecular mechanisms and
novel transcripts governing the progression of disease in MFS, we
performed RNA‐sequencing of aortic tissues from Marfan (mgR/mgR)
vs WT mice and identified several new factors associated with Mar-
fan‐induced aortic disease progression.
2 | MATERIALS AND METHODS
2.1 | Animal experiments and isolation of ascending
aortas from mice
Heterozygous Fbn1 underexpressing mice (25) were mated to gener-
ate homozygous mgR/mgR and WT mice. Genotyping was performed
as previously described.15 Mice were maintained under pathogen‐
free conditions, and the ethical guidelines for animal work and the
animal experiments were approved by the Landesamt für Gesundheit
und Soziales in Berlin (LaGeSo Reg. No. 0024/14). Mice were sacri-
ficed; the ascending aortas and arch of the mgR/mgR homozygous
and WT animals were isolated and pooled for subsequent RNA
expression analysis.
2.2 | Van Giesson staining
Aortic architecture was assessed using elastic van Giesson staining
kit from Sigma‐Aldrich, following the manufacturer's instructions.
2.3 | RNA‐sequencing analysis
Total RNA was extracted from WT and mgR/mgR homozygous ani-
mals (9 weeks old animals) using the RNeasy mini kit (Qiagen). Library
preparation was done using the TruSeq RNA Library Preparation Kit
v2 (Illumina) following the manufacturer's instructions. An Illumina
HiSeq 2500 sequencing device was used to perform the high
throughput sequencing, to generate 65‐75 million reads of 50‐bp
paired‐end reads, with a mean insert size of 150 bp. The reads were
mapped to Mus musculus genome build (mm9) using TopHat2.16
DESeq217 was used for differential expression analysis with a false
discovery rate of 0.05% (FDR).
2.4 | qRT‐PCRs
Freshly dissected aortic tissues were snap‐frozen in liquid nitrogen. Fro-
zen tissues were pulverized and RNA was isolated using Qiagen RNeasy
Mini kit following the manufacturer's instructions. For reverse transcrip-
tion, 1 microgram of RNA was used for conversion into cDNA using the
RevertAid H minus cDNA Synthesis Kit (ThermoFisher Scientific). Real‐
time PCR was performed on the Applied Biosystems 7900HT real‐time
PCR machine as described previously.18 Gapdh was used as endoge-
nous control. Refer to Data S1 for qPCR primers.
2.5 | Western blots
Aortic samples were homogenized using FastPrep®‐24 Classic instru-
ment for 20 seconds. Protein isolation was done using the QIAGEN All-
Prep DNA/RNA/Protein Mini Kit, following the manufacturer's
instructions, in the presence of protease and phosphatase inhibitors.
Proteins were quantified using the Pierce BCA kit. Proteins (30 μg)
were loaded on 10% SDS‐PAGE gels and transferred onto nitrocellulose
membranes. After blocking (3% milk in 0.1% PBS‐T), membranes were
incubated with corresponding primary antibodies overnight at 4°C.
Immunoreactive proteins were detected using ECL Plus (GE Healthcare,
Buckinghamshire, UK). Refer to Data S1 for antibody details.
2.6 | Pathway classification
The gene functional annotation was performed using the DAVID
functional annotation tool19 (https://david.ncifcrf.gov/) followed by
KEGG pathway analysis with an ease score of 0.03 and gene count
of 5 genes per pathway.
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3 | RESULTS
3.1 | Differential gene regulation in the aorta of
WT vs mgR/mgR mice
To identify novel factors and to gain insight into the molecular
mechanisms underlying MFS, we employed mgR/mgR mice compar-
ing them with their WT littermates. First, we performed Van Giesson
staining to assess the elastic architecture of the aortic tissue and we
found the elastic fibres to be fragmented in the mgR/mgR mice com-
pared to WT mice (Figure 1A), a phenomenon commonly seen in
MFS.2,20
Next, we performed RNA‐sequencing of aortic tissues from
homozygous mgR/mgR vs WT mice. Our analysis revealed that 248
genes were differentially regulated between the two groups (Fig-
ure 1B, Table S1), with 144 genes being up‐regulated and 104 being
down‐regulated in WT vs mgR/mgR mice (Table S1). Importantly, our
analysis revealed 20 transcripts previously unknown to be differen-
tially expressed in the aorta of MFS mice (Table S2).
Gene ontology (GO) analysis of the RNA‐sequencing data
revealed the enrichment of gene signatures in GO terms, such as
adrenergic signalling in cardiomyocytes, dilated and hypertrophic car-
diomyopathy (HCM), chemokine signalling, cardiac muscle contrac-
tion and calcium signalling pathway, that are relevant to
cardiovascular complications and MFS (Table 2, Table S3).
We then compared our RNA‐sequencing dataset (9 weeks old
aortas, mgR/mgR mice) to a published microarray dataset (6 weeks
old aortas, mgR/mgR mice) 15 and identified 23 genes to be com-
monly regulated between the two datasets (Figure 1C, Table S4).
Interestingly, 225 genes were exclusively regulated in our dataset
(Table S5), while 126 genes were exclusively regulated in the previ-
ously published microarray dataset15 (Table S6). Furthermore, we
compared our RNA‐sequencing dataset to other aneurysms such as
angiotensin II infused ‐ apolipoprotein deficient mouse model of
abdominal aortic aneurysms (AAA, 17 weeks old aortas)21 and found
36 genes to be common regulated across both datasets (Table S7,
Figure S3).
3.2 | Validation of selected transcripts by qPCR and
Western blotting
We selected and validated the genes randomly (Lrrc17, Gxylt2, Mfs-
d2a, Scube and Ank2) and based on their role in aneurysms
(Mmp12, Spp1, Ctss) or cardiovascular complications (Mfap4, Igfbp2)
or inflammatory signalling pathways (Ccls and Ccrs). Our analysis
revealed that many genes enriched in chemokine signalling (Ccl8,
Ccr5, Ccl9, Ccl6, Ccl7, Ccl2 and Ccl5) were highly induced in mgR/
mgR aortic tissues (Figure 2B,D‐G and Figure S1). Another novel
candidate gene identified from our sequencing analysis, Igfbp2, was
found to be highly up‐regulated across independent biological repli-
cates, suggesting that this might be a potential factor for MFS (Fig-
ure 2A). Other highly up‐regulated candidates of interest were
Spp1, Ctss, Cd55, Cd53, Lmod2, Irf7, Chrdl1, Tmem176b, Lgals3,
MMP12 and H19 LncRNA in mgR/mgR compared to WT mice
F IGURE 1 RNA‐sequencing analysis of
WT vs mgR/mgR aorta. A, Verhoeff‐van
Gieson staining in wild‐type (WT) vs mgR/
mgR mouse. Van Gieson staining was
performed on aortas isolated from wild‐
type and mgR mice. Increased elastin
fragmentation and breaks were observed
in Marfan mice, compared to wild‐type. B,
Differential expression of genes by RNA‐
sequencing analysis in WT vs mgR/mgR
aortas (9 wk) animals. Heatmap depicting
the Log2 FKPM values of significantly
regulated genes (P < 0.05). The red colour
indicates the low expression of genes and
white indicates the high expression of
genes. C, Comparison of our RNA‐
sequencing data to published microarray
(Schwill, Seppelt et al. 2013). Our
comparison identified, 23 genes to be
commonly regulated between both and
225 genes to be exclusively regulated in
our dataset and 126 genes exclusive to
Schwill, Seppelt dataset
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F IGURE 2 Validation of up‐regulated genes from RNA‐sequencing data. A‐E, qPCRs were performed between WT vs mgR/mgR aortas for
the up‐regulated genes from RNA‐sequencing data. Fold changes were calculated and Gapdh was used as normalizing control. Data were
validated across n = 3 different biological replicates. Each replicate is derived from three pooled WT vs mgR tissues (11 weeks old)
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(Figure 2C,H,I and Figure S1). In addition, we also identified and
validated a set of down‐regulated genes by qPCR, such as Lrrc17,
Mfap4, Ncam1, Gxylt2, Mfsd2a, Scube3, Ank2, Dsp, Myh10, Xirp,
Smoc1, Chsy3, Adamts17, ppp1R36, Mylk2, Gucy1b3 and Abcc9 (Fig-
ure 3 and Figure S2). The most significantly up‐ and down‐regu-
lated genes from our RNA‐sequencing data are provided as
Table 1. We further assessed the protein levels of key genes iden-
tified by RNA‐sequencing. pSMAD2 and pErk1/2 signalling path-
ways were induced in mgR/mgR compared to WT mice (Figure 4A,
B). Furthermore, we demonstrated that Igfbp2 and Ccl8 protein
levels are induced (Figure 4C,E) and Mfap4 protein levels are
decreased in mgR/mgR compared to WT mice (Figure 4D), which
correlates with our aortic RNA‐sequencing data. However, we
found Mylk2 protein levels to be increased (Figure 4F), contrary to
decreased mRNA levels in mgR/mgR compared to WT mice (Fig-
ure 3E).
4 | DISCUSSION
In this study, we set out to identify novel differentially expressed
genes during MFS in mgR/mgR aortas using RNA‐sequencing. Our
analysis revealed many previously unknown genes to be significantly
regulated in mgR/mgR mice.
The predominant paradigm of MFS pathophysiology in recent
years has focussed on alterations of TGF‐beta signalling. Moreover,
high levels of circulating TGF‐beta were observed in Marfan mouse
models and patients, suggesting it is an important factor involved in
MFS.22,23 Most of the treatment regimens adopted have been to
antagonize TGF‐beta signalling with neutralizing antibodies or Losar-
tan. However, more recent literature demonstrated that the deletion
of the TGF‐beta receptor II (Tgfbr2) increases the aortopathy in Mar-
fan animals, thus suggesting a complicated role of TGF‐beta sig-
nalling in MFS7,14 and also the possibility of other potential
regulators and mechanisms underlying the MFS phenotype.
To this extent, one of our novel findings is the regulation of Igf-
bp2, which was significantly induced in mgR/mgR vs WT aortas in
our RNA‐ sequencing, qPCR and immunoblotting data. Igfbp2, a
secreted protein, belongs to a class of insulin like growth factor
binding proteins (Igfbp1‐6), which bind to IGF1, IGF2 and insulin and
signal via IGF1R, IGF‐IIR/M6P and insulin receptors, thus transducing
the signal to the nucleus, followed by transcriptional activation of
specific genes to promote proliferation and differentiation. There
have been conflicting reports about the role of Igfbp2 in cancers, as
there is evidence supporting it to be both a tumour suppressor and
an oncogene in different cancers.24 In glioma cells, Igfbp2 promotes
pERK1/2 phosphorylation via integrin β1, thus regulating cell prolifer-
ation and invasion.25 It is known that pERK1/2 levels are induced in
MFS mice and it has been proposed that abolishing pERK1/2 levels
could be a potential therapy towards MFS.11,20
In addition, it was shown that ERK1/2 signalling is limited to non‐
myocyte compartment of MFS mouse heart and upon pressure over-
load, it contributes to cardiomyopathy, emphasizing ERK signalling to
be a crucial therapeutic target in MFS.26 Here, we speculate that the
induced Igfbp2 levels in mgR/mgR mice could be crucial in regulating
pERK1/2 levels in MFS and this needs further investigation.
Furthermore, Mfap4 was highly down‐regulated in mgR/mgR
mice. Mfap4 is an extracellular glycoprotein that specifically binds
tropoelastin, fibrillin‐1 and fibrillin‐2.27 It is expressed in elastic tis-
sues, such as aorta, skin and lung, and is localized to elastic fibres of
these tissues.28–30 In dermal fibroblasts, MFAP4 interacts directly
with fibrillin‐1 and plays a crucial role in microfibril development and
maintenance of ECM proteins.31 In mgR/mgR hypomorphic animals,
Fbn1 levels are low (~20% normal Fbn1 produced) and this corre-
sponds with low level of expression of Mfap4 in our data (RNA‐
sequencing, qPCR and Western), suggesting a possible important
mechanistic role of Mfap4‐fibrillin‐1 interaction in MFS. However,
MFAP4 protein levels were found to be up‐regulated in Marfan
patients,32 suggesting there could be differential regulation of
MFAP4 in different disease model systems or between species. Our
results on Mfap4 shed light on a potentially crucial regulator in MFS
that needs further investigation.
We identified different chemokines to be highly up‐regulated in
MFS (Figure 2D‐G). Medial necrosis and presence of inflammatory
cells is well known in MFS. T cells (CD8+ and CD4+) have been
shown in adventitia of MFS aortas, emphasizing a crucial role of
immune cells in both medial and adventitial layers of MFS aorta.33
Previously, studies have reported inflammatory genes to be involved
in both mouse and human AAA.15,21,34 Among the chemokines identi-
fied in our data, Ccl8 was highly up‐regulated at both RNA (in RNA‐
sequencing, qPCRs datasets) and protein levels. Apart from Ccl8, we
identified Ccr5, Ccl5, Ccl2, Ccl7 and Ccl9, to be highly up‐regulated in
mgR/mgR mice. Ccl8 was also shown to be induced during AAA in
mice.21 The role of IL6‐STAT3 signalling in contributing to aneurysm
dilation has been shown in mgR/mgR Marfan model.35 In MFS
patients, inflammation correlated with aortic disease, emphasizing the
crucial role of inflammatory signalling in aortic disease progression.33
It is known that defective fibrillin‐1 in MFS leads to impaired collagen
and network organization. This might lead to further collagen damage
and the release of degradation products that could possibly activate
inflammatory pathways.33 However, in Fbn1C1039G/+ Marfan model
the anti‐inflammatory therapy did not show beneficial effect on aortic
dilatation, suggesting a complex role of inflammation in different
MFS model systems.36 Overall, it is unclear, if inflammation is the
cause or the consequence of aortic dilation and its role in MFS is not
clearly understood. Collectively, our study reveals the importance of
several inflammatory genes that can be potential targets for novel
anti‐inflammatory therapeutics.
We also found Spp1, Mmp12 and Ctss to be significantly up‐
regulated in mgR/mgR mice. Spp1 is a multifunctional phosphoprotein,
expressed in various cell types and a known biomarker for cardiovas-
cular diseases.6,37 Elevated Spp1 levels have been observed in circula-
tion in different cancers, autoimmune disease and AAA. Spp1 has
been shown to be involved in the regulation of chronic inflammation
and recruitment of T cell and macrophages and regulates cytokine pro-
duction in macrophages and T cells.38 The levels of OPN have been
2530 | BHUSHAN ET AL.
F IGURE 3 Validation of down‐regulated genes from RNA‐sequencing data. A‐G, qPCR was performed between WT vs mgR/mgR aortas for
the down‐regulated genes from RNA‐ sequencing data. Fold changes were calculated and Gapdh was used as a normalizing control. Data were
validated across n = 3 or n = 2 different biological replicates. Each replicate is derived from three pooled WT vs mgR tissues (11 weeks old)
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found to be elevated in AAA patients (both in plasma and aortic wall)
and it may drive AAA formation.39 In addition, the local application of
osteopontin enhanced vascular healing by decreasing the calcification
and maintaining the luminal integrity in rabbit thoracic aortas.40 In
addition, a single SNP in TgfbrII had altered Spp1 secretion after
adjusting for multiple testing.41 However, the mechanistic regulation
of Spp1 in Marfan aortic aneurysms is not clear. It is known that the
complex pathogenesis of MFS involves an imbalance in expression of
matrix metalloproteinases (MMPs) and tissue inhibitors of MMP activ-
ity.42 More specifically, Mmp2, Mmp9 and Mmp12 have been shown
to be up‐regulated in mgR/mgR mice.43 We identified the same trend
in Mmp12 expression. These results emphasize the importance of
Spp1, Ctss andMmp12 in mgR/mgR disease progression.
Apart from coding genes, we also found the H19 LncRNA to be
significantly up‐regulated in mgR/mgR mice. H19 is a conserved and
imprinted lncRNA having many biological functions in different dis-
eases. Increased levels of H19 are associated with increased risk of
coronary artery disease in patients.44 In addition, H19 was induced
in heart failure patients.45 H19 in association with miR‐675 axis was
shown to regulate cardiomyocyte apoptosis and diabetic cardiomy-
opathy.46,47 The same axis (H19‐miR‐675) is reported to function as
a negative regulator of cardiomyocyte hypertrophy in mice.48
TABLE 1 Genes significantly up‐ or down‐regulated in mgR/mgR
aortic aneurysms both in RNA‐sequencing and qPCR datasets
Gene name RNA‐seq and qPCR (in mgR/mgR) P‐value
Igfbp2 Up 5.00E‐05
Mfap4 Down 5.00E‐05
Tmem176b Up 0.00065
Irf7 Up 5.00E‐05
Ccl8 Up 5.00E‐05
Ccl6 Up 0.00025
H19 Up 2.00E‐04
Ccl9 Up 0.00015
Spp1 Up 0.00045
Ctss Up 5.00E‐05
Myh10 Down 0.00035
Lrrc17 Down 5.00E‐05
Scube3 Down 5.00E‐05
Gxylt2 Down 5.00E‐05
Ncam1 Down 5.00E‐05
Mfsd2a Down 0.00015
F IGURE 4 Protein validations of
identified genes from RNA-sequencing
data by Western blots. A) pSmad2 and B)
pErk1/2 protein levels were induced in
mgR/mgR aortic tissues compared to WT
(11 weeks old animals). Up‐regulation of C)
Igfbp2, E) Ccl8 and F) Mylk2 protein levels
and Down‐regulation of D) Mfap4 protein
levels in mgR/mgR aortic tissues compared
to WT. Protein lysates were harvested as
described in methods sections. Gapdh or
Hsp60 was used as a loading control
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However, the role of H19 in context of MFS is unclear and we
believe it could be an interesting target to investigate.
Moreover, we identified several genes to be commonly regulated
between our RNA‐ sequencing dataset and a previously published
microarray datasets,15,21 suggesting the significance and importance of
these genes in MFS. Furthermore, our approach identified several
genes, such as Lrrc17, Mfap4, Ncam1, Gxylt2, Mfsd2a, Scube3, Ank2,
Dsp, Myh10, Xirp, Smoc1, Chsy3, Adamts17, ppp1R36, Mylk2, Gucy1b3
and Abcc9 to be significantly down‐regulated in mgR/mgR aortas, whose
regulation has not been previously related to MFS. However, we found
Mylk2 protein levels to be induced in mgR/mgR mice, suggesting possi-
ble posttranscriptional regulation of this particular gene.
GO analysis of differentially regulated genes revealed relevant
pathways involved in cardiovascular biology and MFS, such as adrener-
gic signalling in cardiomyocytes, dilated cardiomyopathy, HCM, cal-
cium signalling pathway, chemokine signalling pathway and others
(Table 2). The crucial role of adrenergic signalling in cardiac diseases is
recognized. It is known that hyperactivity of β‐adrenergic signalling
and increase in ROS production contribute to cardiac hypertrophy and
heart failure.49,50 In addition, β‐adrenergic blockade using propranolol
decreased the aortic dilatation and complications and improved the
clinical manifestations of MFS,51,52 emphasizing its crucial role in MFS.
The other GO enriched pathway from our data was dilated cardiomy-
opathy that has been shown to be the primary manifestation of MFS,
which results from ECM‐induced abnormal mechanosignalling by car-
diomyocytes.53 Furthermore, dilated cardiomyopathy in an MFS
patient was accompanied by chronic type A aortic dissection and right
atrial thrombus.54 We also found calcium signalling pathway to be
overrepresented in our dataset. It is known that calcium influx regu-
lates FBN1 expression.55 Moreover, calcium channel blockers, are used
as a second line of therapy in 10%‐20% MFS patients who are intoler-
ant to β‐blockers.56 However, calcium channel blockers have detrimen-
tal effects in MFS mice and are associated with an increased risk of
cardiovascular pathology in human MFS.57 All these data, highlight the
importance of our finding on calcium signalling and its implication in
MFS management. Apart from the above mentioned pathways, our
data also emphasized the importance of chemokine signalling, which is
crucial during MFS.33 However, the exact role of chemokine signalling
in MFS is still unclear. The other pathways from our GO analysis, such
as focal adhesion, HCM and cardiac muscle contraction have also been
implicated in MFS.58–60 Overall, our GO analysis suggests a specific
and crucial role of identified genes and pathways that are relevant in
mgR/mgR mice.
In conclusion, our analysis expands the understanding of the
pathobiology of Marfan disease progression. Our analysis revealed
several genes previously unknown to be involved in aorta‐specific
Marfan disease that may be important targets for designing more
appropriate therapeutic strategies for the treatment of MFS.
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